<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35193574</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1741-7015</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>23</Day></PubDate></JournalIssue><Title>BMC medicine</Title><ISOAbbreviation>BMC Med</ISOAbbreviation></Journal><ArticleTitle>Long COVID 12 months after discharge: persistent symptoms in patients hospitalised due to COVID-19 and patients hospitalised due to other causes-a multicentre cohort study.</ArticleTitle><Pagination><StartPage>92</StartPage><MedlinePgn>92</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">92</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12916-022-02292-6</ELocationID><Abstract><AbstractText Label="BACKGROUND">Long-term-specific sequelae or persistent symptoms (SPS) after hospitalisation due to COVID-19 are not known. The aim of this study was to explore the presence of SPS 12 months after discharge in survivors hospitalised due to COVID-19 and compare it with survivors hospitalised due to other causes.</AbstractText><AbstractText Label="METHODS">Prospective cohort study, the Andalusian Cohort of Hospitalised patients for COVID-19 (ANCOHVID study), conducted in 4 hospitals and 29 primary care centres in Andalusia, Spain. The sample was composed of 906 adult patients; 453 patients hospitalised due to COVID-19 (exposed) and 453 hospitalised due to other causes (non-exposed) from March 1 to April 15, 2020, and discharged alive. The main outcomes were (1) the prevalence of SPS at 12 months after discharge and (2) the incidence of SPS after discharge. Outcome data at 12 months were compared between the exposed and non-exposed cohorts. Risk ratios were calculated, and bivariate analyses were performed.</AbstractText><AbstractText Label="RESULTS">A total of 163 (36.1%) and 160 (35.3%) patients of the exposed and non-exposed cohorts, respectively, showed at least one SPS at 12 months after discharge. The SPS with higher prevalence in the subgroup of patients hospitalised due to COVID-19 12 months after discharge were persistent pharyngeal symptoms (p&lt;0.001), neurological SPS (p=0.049), confusion or memory loss (p=0.043), thrombotic events (p=0.025) and anxiety (p=0.046). The incidence of SPS was higher for the exposed cohort regarding pharyngeal symptoms (risk ratio, 8.00; 95% CI, 1.85 to 36.12), confusion or memory loss (risk ratio, 3.50; 95% CI, 1.16 to 10.55) and anxiety symptoms (risk ratio, 2.36; 95% CI, 1.28 to 4.34).</AbstractText><AbstractText Label="CONCLUSIONS">There was a similar frequency of long-term SPS after discharge at 12 months, regardless of the cause of admission (COVID-19 or other causes). Nevertheless, some symptoms that were found to be more associated with COVID-19, such as memory loss or anxiety, merit further investigation. These results should guide future follow-up of COVID-19 patients after hospital discharge.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rivera-Izquierdo</LastName><ForeName>Mario</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6159-6037</Identifier><AffiliationInfo><Affiliation>Department of Preventive Medicine and Public Health, University of Granada, Avenida de la Investigaci&#xf3;n 11, 18016, Granada, Spain. mariorivera@ugr.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service of Preventive Medicine and Public Health, Hospital Universitario San Cecilio, Granada, Spain. mariorivera@ugr.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Biosanitario de Granada (ibs. GRANADA), Granada, Spain. mariorivera@ugr.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xe1;inez-Ramos-Bossini</LastName><ForeName>Antonio Jes&#xfa;s</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Service of Radiology, Hospital Universitario Virgen de las Nieves, Granada, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Alba</LastName><ForeName>Inmaculada Guerrero-Fern&#xe1;ndez</ForeName><Initials>IG</Initials><AffiliationInfo><Affiliation>Service of Preventive Medicine and Public Health, Hospital Universitario San Cecilio, Granada, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortiz-Gonz&#xe1;lez-Serna</LastName><ForeName>Roc&#xed;o</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Service of Preventive Medicine and Public Health, Hospital Universitario Reina Sof&#xed;a, C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Preventive Medicine and Public Health Research Group, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano-Ortiz</LastName><ForeName>&#xc1;lvaro</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>Service of Preventive Medicine and Public Health, Hospital Universitario Reina Sof&#xed;a, C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Preventive Medicine and Public Health Research Group, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Mart&#xed;nez</LastName><ForeName>Nicol&#xe1;s Francisco</ForeName><Initials>NF</Initials><AffiliationInfo><Affiliation>Service of Preventive Medicine and Public Health, Hospital Universitario Reina Sof&#xed;a, C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Preventive Medicine and Public Health Research Group, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz-Montero</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Service of Preventive Medicine and Public Health, Hospital Universitario Reina Sof&#xed;a, C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Preventive Medicine and Public Health Research Group, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cervilla</LastName><ForeName>Jorge A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Granada, Granada, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med</MedlineTA><NlmUniqueID>101190723</NlmUniqueID><ISSNLinking>1741-7015</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010351" MajorTopicYN="N">Patient Discharge</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cohort study</Keyword><Keyword MajorTopicYN="N">Follow-up</Keyword><Keyword MajorTopicYN="N">Long term</Keyword><Keyword MajorTopicYN="N">Persistent COVID-19</Keyword><Keyword MajorTopicYN="N">Sequelae</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>23</Day><Hour>5</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35193574</ArticleId><ArticleId IdType="pmc">PMC8863509</ArticleId><ArticleId IdType="doi">10.1186/s12916-022-02292-6</ArticleId><ArticleId IdType="pii">10.1186/s12916-022-02292-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Estiri H, Strasser ZH, Brat GA, Semenov YR, Patel CJ, Murphy SN, Consortium for characterization of COVID-19 by EHR (4CE) Evolving phenotypes of non-hospitalized patients that indicate long COVID. BMC Med. 2021;19(1):249. doi: 10.1186/s12916-021-02115-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02115-0</ArticleId><ArticleId IdType="pmc">PMC8474909</ArticleId><ArticleId IdType="pubmed">34565368</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson G, Long Covid Forum Group Research priorities for long COVID: refined through an international multi-stakeholder forum. BMC Med. 2021;19(1):84. doi: 10.1186/s12916-021-01947-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-01947-0</ArticleId><ArticleId IdType="pmc">PMC8009733</ArticleId><ArticleId IdType="pubmed">33785027</ArticleId></ArticleIdList></Reference><Reference><Citation>Deuel JW, Schlagenhauf P. In for the long-haul? Seropositivity and sequelae 1 year post COVID-19. BMC Med. 2021;19(1):200. doi: 10.1186/s12916-021-02084-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02084-4</ArticleId><ArticleId IdType="pmc">PMC8437657</ArticleId><ArticleId IdType="pubmed">34517856</ArticleId></ArticleIdList></Reference><Reference><Citation>Peghin M, Palese A, Venturini M, De Martino M, Gerussi V, Graziano E, et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clin Microbiol Infect. 2021;27:1507&#x2013;1513. doi: 10.1016/j.cmi.2021.05.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.05.033</ArticleId><ArticleId IdType="pmc">PMC8180450</ArticleId><ArticleId IdType="pubmed">34111579</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F. Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautam N, Madathil S, Tahani N, Bolton S, Parekh D, Stockley J, et al. Medium-term outcomes in severerily to critically ill patients with severe acute respiratory syndrome coronavirus 2 infection. Clin Infect Dis. 2022;74(2):301&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8135551</ArticleId><ArticleId IdType="pubmed">33893486</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Committee for the COMEBAC Study Group. Morin L, Savale L, Pham T, Colle R, Figueiredo S, et al. Four-month clinical status of a cohort of patients after hospitalization for COVID-19. JAMA. 2021;325(15):1525&#x2013;1534. doi: 10.1001/jama.2021.3331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.3331</ArticleId><ArticleId IdType="pmc">PMC7970386</ArticleId><ArticleId IdType="pubmed">33729425</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivan M, Taylor S. NICE guideline on long COVID. BMJ. 2020;371:m4938. doi: 10.1136/bmj.m4938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m4938</ArticleId><ArticleId IdType="pubmed">33361141</ArticleId></ArticleIdList></Reference><Reference><Citation>Boscolo-Rizzo P, Guida F, Polesel J, Marcuzzo AV, Capriotti V, D'Alessandro A, et al. Sequelae in adults at 12 months after mild-to-moderate coronavirus disease 2019 (COVID-19). Int Forum Allergy Rhinol. 2021;1(12):1685&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9291310</ArticleId><ArticleId IdType="pubmed">34109765</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, et al. Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study. Clin Infect Dis. 2021:ciab611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Data Science Collaborative Group Differences in clinical deterioration among three subphenotypes of COVID-19 patients at the time of first positive test: results from a clustering analysis. Intensive Care Med. 2021;47(1):113&#x2013;115. doi: 10.1007/s00134-020-06236-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-06236-7</ArticleId><ArticleId IdType="pmc">PMC7569095</ArticleId><ArticleId IdType="pubmed">33074342</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I, et al. Post-covid syndrome in individuals admitted to hospital with COVID-19: retrospective cohort study. BMJ. 2021;372:n693. doi: 10.1136/bmj.n693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n693</ArticleId><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E, Janvier P, Kherabi Y, Le Bot A, Hamon A, Gouze H, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020;81(6):e4&#x2013;e6. doi: 10.1016/j.jinf.2020.08.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.08.029</ArticleId><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Behnood SA, Shafran R, Bennett SD, Zhang AXD, O'Mahoney LL, Stephenson TJ, et al. Persistent symptoms following SARS-CoV-2 infection amongst children and young people: a meta-analysis of controlled and uncontrolled studies. J Infect. 2021;S0163-4453(21):00555&#x2013;00557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8604800</ArticleId><ArticleId IdType="pubmed">34813820</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero-Duarte &#xc1;, Rivera-Izquierdo M, Guerrero-Fern&#xe1;ndez de Alba I, P&#xe9;rez-Contreras M, Fern&#xe1;ndez-Mart&#xed;nez NF, Ruiz-Montero R, et al. Sequelae, persistent symptomatology and outcomes after COVID-19 hospitalization: the ANCOHVID multicentre 6-month follow-up study. BMC Med. 2021;19(1):129. doi: 10.1186/s12916-021-02003-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02003-7</ArticleId><ArticleId IdType="pmc">PMC8134820</ArticleId><ArticleId IdType="pubmed">34011359</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen AJ, Mary-Krause M, Bustamante JJH, H&#xe9;ron M, El Aarbaoui T, Melchior M. Symptoms of anxiety/depression during the COVID-19 pandemic and associated lockdown in the community: longitudinal data from the TEMPO cohort in France. BMC Psychiatry. 2021;21(1):381. doi: 10.1186/s12888-021-03383-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12888-021-03383-z</ArticleId><ArticleId IdType="pmc">PMC8316881</ArticleId><ArticleId IdType="pubmed">34320943</ArticleId></ArticleIdList></Reference><Reference><Citation>Fergus TA, Kelley LP, Griggs JO. The combination of health anxiety and somatic symptoms: specificity to anxiety sensitivity cognitive concerns among patients in primary care. Psychiatry Res. 2016;239:117&#x2013;121. doi: 10.1016/j.psychres.2016.02.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2016.02.067</ArticleId><ArticleId IdType="pubmed">27137971</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236&#x2009;379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5):416&#x2013;427. doi: 10.1016/S2215-0366(21)00084-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(21)00084-5</ArticleId><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>